Overview

Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

Status:
Withdrawn

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

This is a safety study of tandutinib in combination with temozolomide and bevacizumab after people have received radiation therapy and temozolomide treatment. This study will determine the maximum safe dose of tandutinib when combined with temozolomide and bevacizumab and evaluate the safety of the combination treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Bevacizumab
Dacarbazine
Temozolomide